How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?

Pediatric Pulmonology

Volumn 39, Issue 6, 2005, Pages 504-506

  VanDevanter, Donald R ^a,b   Van Dalfsen, Jill M ^a  

^a Chiron Corporation   (United States)

^b NONE   (United States)

Author keywords

Antibiotic susceptibility; Biofilm; Exacerbation; Planktonic; Pseudomonas; Resistance

Indexed keywords

ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFTAZIDIME; PIPERACILLIN; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BIOFILM; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SYMPTOMATOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BIOFILMS; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 18844373631     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20220     Document Type: Review

References (28)

1. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
2. Høiby N, Johansen HK, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001;3:23-35.
3. Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002;347:1110-1111.
4. Moskowitz SM, Foster JM, Emerson E, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004;42:195-1922.
5. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock RE, Parsek MR, Noah TL, Boucher RC, Hassett DJ. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002;3:593-603.
6. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatuyar K, Kamani MC, Wozniak DJ, Hwang S-H, McDermott TR, Ochner UA. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002;54:1425-1143.
7. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188.
8. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51.
9. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction in sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
10. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002;17:47-56.
11. Costerton JW. Anaerobic biofilm infections in cystic fibrosis. Mol Cell 2002;10:699-700.
12. De Boeck K, Breysem L. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother 1998;41:407-409.
13. Reed MN, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987;3:101-109.
14. McLaughlin FJ, Mathews WJ Jr, Strieder DJ, Sullivan B, Taneja A, Murphy P, Goodman DA. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983;147:559-567.
15. Penketh A, Hodson ME, Gaya H, Batten JC. Azlocillin compared with carbenecillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax 1984;39:299-304.
16. Smith AL, Doershuk C, Goldmann D, Gore E, Human B, Marks K, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. Comparison of a β-lactam alone versus a β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134:413-421.
17. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992;24:215-218.
18. Prince A. Antibiotic resistance of Pseudomonas aeruginosa species. J Pediatr 1986;108:830-834.
19. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-796.
20. Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979;140:873-880.
21. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-642.
22. Cobb LM, Mychaleckyj JC, Wozniak DJ, López-Boado YS. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J Immunol 2004;173:5659-5670.
23. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev K-M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
24. Barth AL, Pitt TL. Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild-type strains in respiratory infections in patients with cystic fibrosis. J Clin Microbiol 1995;33:37-40.
25. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotype variation. Nature 2002;416:470-473.
26. Häussler S, Tümmler B, Weissbrodt H, Rohde M, Steinmetz I. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999;29:621-625.
27. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis. Chest 2003;123:1495-1502.
28. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.